Instead of a complete blockade of tumor vessel formation, some of anti-angiogenic therapies, including VEGFR kinase inhibitors cediranib and SU5416, an anti-VEGFR antibody DC101, and a PDGFR kinase inhibitor SU6668, ameliorate vascular normalization and alleviate peritumoral edema in GBMs and other cancers (Table 1 & 2) [86–90]. The gene discussed is KDR; the disease is neoplasm.